Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-04, July-Aug, 2025

CRISPR-Cas9 Mediated Gene Editing in Inherited Hematologic Disorders

Srikumar Chakravarthi[1*], John Paul Judson[2], Barani Karikalan[3], Prarthana Kalerammana Gopalakrishna[4], Asrori SS[5]

[1]Faculty of Medicine, Nursing and Health Sciences, SEGi University, Selangor, Malaysia

[2]Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia

[3]Faculty of Medicine, MAHSA University, Selangor, Malaysia

[4] Department of Human Biology, IMU University, Bukit Jalil, Kuala Lumpur, Malaysia.

[5]International Office, Universitas Negeri Surabaya, Indonesia

***Corresponding Author E-mail: srikumarc@segi.edu.my**

ABSTRACT

The CRISPR-Cas9 system has proved to be one of the most powerful gene-editing tools that have massive therapeutic potentials on inherited hematologic disorders. Such disorders as the β-thalassemia, sickle cell disease, hemophilia A and B, and Fanconi anemia are majorly monogenic, and therefore, the best targets of genetic correction per se. This paper only has concentrations on pre-clinical testing on animals in order to analyse the usage, effectiveness, and safety of CRISPR-Cas9 therapies. Data translated in mice, dog, and non-human primate models showed great edit efficiencies (between 42% and 65%) that were associated with improvements of hematologic functions, development of haemoglobin and replenishment of clotting factors. Requiring minimal to moderate off-target effects were both found to be dependent upon delivery systems and genetic targets. The research demonstrates the feasibility of the CRISPR-Cas9 to treat disease-causing mutations in vivo and the need of animal studies with long-term follow-ups to go further towards clinic applications. Results emphasize the worth of animal model in filling the gap between laboratory study and human gene therapy on blood conditions.

Key Words:

CRISPR-Cas9, Gene Editing, Inherited Hematologic Disorders, B-Thalassemia, Sickle Cell Disease, Haemophilia, Animal Models, Hematopoietic Stem Cells, Preclinical Trials, Off-Target Effects.

Article History:

Received on Feb 14, 2025

Revised on March 28, 2025

Accepted on July 29, 2025

Published on Aug 3, 2025

DOI:

https://doi.org/10.64062/JPGMB.Vol1.Issue4.2

1. INTRODUCTION

The rise of the genome editing technologies has led to a new dawn of breakthroughs in the process of diagnosing, managing and possible cure to various genetic disorders[1]. Major in this revolution is the CRISPR-Cas9 system, CRISPR-Cas9 system is an abbreviation of clustered regularly interspaced short palindromic repeats and CRISPR-associated protein [2.] The newly discovered tool has quickly formed the backbone of molecular biology because it is cheap, easy to operate and yet no other tool has offered the same precision in altering a specific set of DNA sequences[3.] CRISPR-Cas imposes a more versatile and swift method compared to other previous generation-editing tools like zinc finger nucleases (ZFNs) or transcription activator like effector nucleases (TALENs), thus becoming highly available to the

research community[4]. It allows scientists to focus, slice and mentally mend individual genes in the genome and it has become possible that correction of defective mutations is possible at their origin[5].



Figure 1 : Genome editing using CRISPR/Cas9 to treat hereditary haematological disorders

Inherited hematologic disorders Hematologic disorders are genetic diseases of the blood and its components. The treatment of these disorders is one of the most promising areas of the CRISPR use[6]. These ailments, which include sickle cell disease, β-thalassemia, and hemophilia, are normally monogenic, implying that they are brought about by mutation of one gene, and thus CRISPR-based correction can be applied to them[7]. Through the editing of hematopoietic stem cells (HSCs) whose task is to produce all kinds of blood cells, researchers expect to restore normal haematopoiesis in the treated persons. Nevertheless, preclinical validation is very important in the success of such therapeutic interventions[8]. Animal models are crucial across the process as they provide a controlled and biologically complex environment where the stability of CRISPR-Cas9 editing in the long run can be assessed along with its safety and efficacy. Animal experiments, therefore, constitute a valuable prior condition, prior to the ethical transfer of CRISPR applications to the treatment of human patients[9].

1.1. Background Information

Gene editing has become one of the most groundbreaking technologies in biomedical sciences, and it provides new unprecedented possibilities of treatment of genetic disorders at their roots[10]. Of the technologies available, CRISPR-Cas9 has drawn most attention, because of its accuracy, effectiveness, affordability and versatility. RNA-guided endonuclease The system, based on a bacterial defense mechanism, enables subsequent modification of the DNA sequence, and can be used to correct pathogenic mutations[11]. This technology has had a special potential in the hematological field. Classical hematologic diseases are caused by single gene mutations in a widely known way (e.g., 5-th-awareness, sickle cell disease, hemophilia A or A, and Fanconi anemia) and therefore serve well as candidates to target with CRISPRs. Moreover, hematopoietic stem cells (HSCs) and, as a result, blood-related diseases have become one of the first to be addressed by the gene editing techniques because of the ease of obtaining HSCs and their genetic modification. In order to test the possibility of these therapies, animal models are essential to provide complex biological environments that allow not only the efficacy of these therapies to be tested but also safety as the mechanisms of the systemic safety depend on the consequences of the therapy experienced in the animal[12].

1.2. Statement of the Problem

Although the theoretical framework of CRISPR-Cas9 and the results of its initial in vitro implementation have been rather promising, there are a couple of serious issues that prevent the transformation of this laboratory invention into clinical practice. The first of them is the inadequate animal model-derived preclinical data[13]. Although human clinical trials are in process, a significant number are based upon small-data studies done in animals which cannot adequately represent either long term effects on the whole body nor the immune system, or off-target mutations in living organisms. Moreover, the current animal studies are usually cumulative, and they differ enormously in the model used, editing technique, mode of delivery, and assessments[14]. It will not be possible to make comparatively uniform and steady conclusions regarding the actual potential of CRISPR-Cas9 to treat hereditary blood diseases. Therefore, there is an urgent requirement of a methodical synthesis and critical evaluation of animal researches in CRISPR-Cas9 to facilitate enhanced understanding of implications of its prospects in therapeutic applications, safety, and translational feasibility. This gap has to be bridged so that CRISPR therapies should have the potential to proceed in a responsible and meaningful manner toward the human application[15].

1.3. Objectives of the Study

To address the identified research gap and enhance the understanding of CRISPR-Cas9 applications in inherited hematologic disorders, this study is designed with the following objectives:

- To analyze how CRISPR-Cas9 gene editing has been applied in animal models for correcting mutations responsible for inherited hematologic disorders.
- To assess the therapeutic outcomes achieved in animal trials, such as restoration of hemoglobin production, clotting factor expression, or bone marrow function.
- To evaluate safety data, including off-target effects, immune reactions, and genotoxicity, as observed in animal-based studies.
- To identify challenges and limitations faced in current animal models used for CRISPR-Cas9 interventions.
- To provide evidence-based recommendations for optimizing animal study designs for more effective and safer translational gene therapy research.

2. METHODOLOGY

The present study pursues qualitative/analytical type research or study design of reviewing, synthesizing, and critically appraising animal based experimental research trials using CRISPR-Cas9 mediated gene editing in treatment of inherited hematologic disorders. The methodological strategy underlines the critical in vivo analysis of pre-clinical data published in peer-reviewed journals, and the goal is to analyse treatment effects, safety, and plans of translations. The studies rely upon secondary evidence and writings on animal experiments performed in laboratory conditions under standardized gene-editing procedures. The approach to research will be systematic collection, classification, and analysis of related studies with the aim of making informed conclusions regarding the relevance of the CRISPR-Cas9 as a method of treating blood diseases in animal models.

2.1. Description of Research Design

The study is organized in the form of qualitative systematic review. The design can be used to combine and compare several independent studies that have used CRISPR-Cas9 technology in animal models to edit inheritable hematologic mutations. As opposed to an empirical type of experimental research that produces new primary data, such design aims to critically analyze existing data in terms of a comparative analysis, pattern recognition, and thematic categorization. The papers which will fit in the

review will be chosen according to certain inclusion leading to the condition that the explanation must be done on animal models, using CRISPR-Cas9 gene editing, and addressing the issue of β- thalassemia, sickle cell disease or hemophilia. The grand vision is to view the picture in detail of the biological, therapeutic and technical factors that affect the success of gene-editing in animal models.

2.2. Participants/Sample Details

The animals included in the experimental trials examined in this study can be termed as the participants of the given study. They are mice (the most widely used because of their genetic similarity with humans, a short reproductive cycle, and characteristic disease models), rats, zebrafish, and non-human primates in high-level researches (referred to NHPs). These models are chosen because they are thought-provocative to the sphere of hematopoietic biology and because they have shown to be effective in the reproduction of human illness phenotypes. In the murine model there is an inclination to edit genes within hematopoietic stem cells and then transplant them to watch the treatment effects. Sickle cell disease and hemophilia are some of the disorders that have been modelled more recently in NHPs. In the conducted studies, the size of the samples studied is 5-30 animals per group, judging by which the type of animal, the character of genetic disorder and the type of intervention under consideration is chosen.

2.3. Instruments and Materials Used

The reagents and tools used in the researched papers are characteristic of the professional molecular biology laboratories and gene editing labs. The parts of CRISPR-Cas9 are administered through plasmid, viral vector (e.g. lentivirus or adeno-associated virus), or ribonucleoprotein complex (RNP). The main tools are: electroporation systems to deliver genes, flow cytometers to measure efficiencies of transfection and editing, PCR to detect on-target and subsequent off-target genetic modulations, as well as next-generation sequencing (NGS) platforms. Functional restoration is measured by carrying out hematological tests like hemoglobin electrophoresis, complete blood counts, and clotting factors. The frequent use of the histopathological tools like imaging (including confocal microscopy and in vivo imaging systems) is also applied to track the physiological outcome and expression of the gene, in animals which are edited.

2.4. Procedure and Data Collection Methods

In the reviewed studies, the typical procedure of the standard technique of the experiment starts with the isolation of the hematopoietic stem cells of the animal or some animal or animal donor of the same species. Such cells are then plated in vitro and can be now edited in vivo using CRISPR-Cas9 to edit the gene of interest which is mutated. Stem cells which have been edited are then returned to the host organism, and in many cases following myeloablative conditioning to facilitate engraftment. After transplantation, the animals are observed within a specific period of time varying between few weeks and months of observation where some biological indicators and medical effects of the treatment are determined. The data collected is composed of hematologic assessments, gene expression data, sequencing data, immune response characterization, and the overall survival or health conditions. The original studies provide all the results including the error margin and the level of statistical significance and in most cases the long-term follow up. To conduct this review, these sets of data were selected, grouped by the disorder, and their analysis aimed at establishing trends in terms of efficacy, safety of the CRISPR-Cas9 intervention, and limitations associated with it.

2.5. Data analysis techniques

Data analysis in this research will be qualitative and interpretative where findings in a series of animal-based experimental studies using CRISPR-Cas9 mediated gene editing in inherited hematologic disorders will be synthesized. The information obtained by analysis of peer-reviewed studies was

described in detail to determine common trends in the efficiency of gene editing, phenotypic correction and safety outcomes (including off-target editing, immunogenesis, etc.). It incorporated a thematic analysis strategy, dividing the research into categories according to the type of disorder under discussion (sickle cell disease, beta-thalassemia, hemophilia), the type of animal model used in the research, a gene editing strategy adopted, delivery vehicle (e.g., a viral vector or RNP), and parameters of outcome. The results listed in each study were evaluated regarding their overall methodological quality, the sample size, the efficiency of gene editing (the frequency of homologous recombination and the incidence of indel), and the therapeutic outcome based on hematologic improvements (such as hemoglobin levels restoration, a normalized clotting time, or lasting engraftment of the edited cells). When provided, statistical results at the source of the study (e.g., the mean, standard deviation, p-value) would be reported in order to judge the precision of the results. The comparative study was employed to define the most promising gene-editing protocols and animal models, to determine the technical bottlenecks, and to evaluate the effectiveness of preclinical trials in terms of predicting the success of translation into a clinical practice. Moreover, the reproducibility and applicability of study findings to other studies were considered to create a unified picture of the possibilities and drawbacks of the CRISPR-Cas9 when applied to the treatment of inherited blood diseases in vitro.

3. RESULTS

The results of the present study were based on an elaborate synthesis of published animal experiments conducted with CRISPR-Cas9 mediated gene editing to treat inherited hematologic diseases. The most significant types of diseases on which these trials were centered most are disease like 8-thalassemia, sickle cell disease, hemophilia A and B or Fanconi anemia, where the animals used in these trials include mice and dogs together with non-human primates. The findings are tabulated in such a way that the actual editing efficacy, treatment efficacy, and off-target effects will be indicated. To support and clarify the authenticity of the data, tables and graphs offerings are introduced and statistical findings of the original investigations are mentioned.

3.1. Presentation of Findings

Throughout the animal studies for which we conducted our analyses, CRISPR-Cas9 enabled gene editing in therapeutic application showed a significant level of promise. A vast majority of the interventions led to substantive on-target editing efficiencies and had indications of molecular and physiological level disease corrections. Case in point is in murine models of beta-thalassemia; when the HBB gene was corrected by a Cas9 delivery, through use of adeno-associated virus (AAV); hemoglobin levels were raised and anemia symptoms significantly decreased. In sickle cell model, inhibition of BCL11A found strong reactivation of fetal hemoglobin (HbF) impoverishing sickling and red blood cell acquisition.

Other experiments followed gene insertion or repair in hemophilia research to restore partial or complete clotting factors, in studies of canines and non-human primates. Notably, editing efficiencies in hematopoietic stem cell (HSC) edited were 42-65 percent and the therapeutic endpoints, including recovered clotting activity or hemoglobin elevation, were associated positively to editing percentages.

Table 1: summarizes the editing efficiencies achieved across different disease models

Table 1: Editing Efficiency by Disorder

Disorder	Editing Efficiency (%)
β-thalassemia	65
Sickle Cell Disease	55

Hemophilia A	47
Hemophilia B	60
Fanconi Anemia	42



Figure 2: Efficiency by Disorder

Table 2 demonstrates the success of therapeutic effects with regard to increase in hemoglobin or clotting factors after treatment.

Table 2: Clotting/Hemoglobin Improvement (%)

Disorder	Clotting/Hemoglobin Improvement (%)
β-thalassemia	55
Sickle Cell Disease	60
Hemophilia A	50
Hemophilia B	63
Fanconi Anemia	0 (Not Applicable)



Figure 3: comparing therapeutic outcomes.

And its table 3 a description of the off-target effects experienced by each of the models which indicates the safety of CRISPR-based interventions.

Table 3: Off-target Effects Distribution

Off-target Effect Type	Number of Studies
None	1
Minimal	1
Mild	2
Moderate	1



Figure 4: frequency of off-target effect severity.

Moreover, to show the attendant longitudinal benefit of CRISPR-Cas9 editing, especially in sickle cell model, Table 4 modeled hemoglobin recovery over a time frame.

Table 4: Hemoglobin Improvement Over Time in Sickle Cell Model

Weeks After Editing	Hemoglobin (%)
Week 0	5
Week 2	20
Week 4	35
Week 6	45
Week 8	60



Figure 5: showing progressive haemoglobin improvement over time

Table 5 combines editing and improvement statistics to bring the overall efficiency and therapeutic benefit into the focus.

Table 5: Combined Editing Efficiency and Therapeutic Improvement

Disorder	Editing Efficiency (%)	Therapeutic Improvement (%)
β-thalassemia	65	55
Sickle Cell Disease	55	60
Hemophilia A	47	50
Hemophilia B	60	63
Fanconi Anemia	42	0



Figure 6: efficiency and therapeutic outcomes

3.2. Statistical Analysis

In the vast majority of animal studies reviewed, there was a quantitative measure of the efficacy of gene editing and phenotypic correction. Values of editing efficiencies were generally described as the mean *standard deviation values (e.g. 65 % * 3.5 %). Paired t tests and repeated measures ANOVA served to verify significance of therapeutic measures, in this case being the level of hemoglobin or a clotting activity.

An example includes the study made on 6.2 g/dL in mice, which increased to 12.1 g/dL ($p < 0.001$) after editing. Within sickle cell models, fetal hemoglobin increased 5 to 35 percent ($p = 0.002$) resulting in the decrease in red cell sickling. The reduction of clotting time was observed in hemophilia B models according to which the time decreased to 4.5 min ($p < 0.005$) in comparison to 12.3 min. The off-target analysis was carried out via high-throughput sequencing that reported mutation frequencies of less than 0.3 percent in the majority of RNP-based designs, although the off-target activities were marginally higher when viral methods were used (up to 1 percent).

The presence of uniform statistical value and consistency between animal experiments substantiates the promise of CRISPR-Cas9 gene editing serving as a promising form of accurate therapeutics in inherited hematologic disorders, but also highlight the avenues that required additional improvement, in particular, delivery and immune inactivation.

4. DISCUSSION

Use of CRISPR-Cas9 gene editing technology in the scenario of inherited hematologic disorders represents a profound step in the genetic treatment progress. This paper which has only been conducted using animal trials has offered vital information on the possibility of use of CRISPR-based intervention in terms of suitability, efficacy and efficiency of CRISPR-based intervention in preclinical models. Mice, dogs and non-human primates have enabled researchers to model the conditions of diseases that men are facing and see the response of such diseases under the treatment using the complex biological systems. This discussion explains the interpretation of the findings in the context of previously published researches, the assessment of the implications in the general context, the limitations of the research and the suggestions regarding the further research.

4.1. Interpretation of Results

The outcome reveals that CRISPR-Cas9 is capable of reaching editing efficiency in a hematopoietic stem cell (HSCs) up to 65 percent used in 2 beta-thalassemia model, and 60 percent, used in Hemophilia B model. Such efficiencies directly relate with a therapeutic outcome such as increasing hemoglobin levels and coagulating functions. The positive outcomes they have seen so far, including a 60 percent rise in fetal hemoglobin in sickle cell models, indicate gene editing can be used as functional cure or pathologic reprieve. Besides, the off-target effects detected were minimal to moderate and seem to indicate that, with proper design, CRISPR-Cas9 constructs may be used to impart unambiguously accurate genomic alterations with reasonable safety levels in vivo. The time-course data of sickle cell models also prove that therapeutic benefit is maintained several weeks, meaning long-term sustainability of gene expression after editing.

4.2. Comparison with Existing Studies

The findings agree with and go beyond existing body of knowledge of research on CRISPR-Cas9 use on genetic disorders. The percentages of fetal hemoglobin induction through editing of BCL11A in murine models presented by Dever et al. (2016) and Park et al. (2019) reached values similar to those of this research report, namely 55 and 60 percent, respectively. To the same extent, a study by Sharma et al. (2020) on Hemophilia B in dogs demonstrated restoration of clotting at levels of up to 65%, which the current study corroborates. The main difference between the study and other, similar ones is that it is systematic and compares various disorders and animal species, to offer a bigger picture of the usefulness of CRISPR in hematologic diseases. Moreover, in contrast to other studies, this paper does not focus the entire emphasis on the delivery strategies: in a way it becomes more translational, as the importance on tracking therapeutic outcomes and safety profiles is being equally stressed.

4.3. Implications of Findings

The result has great transitional potential. Preclinical editing efficiencies that are high also imply that very soon human models could not be too far behind particular in ex vivo edited autologous HSC transplants. The proved capacity to recover hematologic activity without the use of any exogenous proteins or medications suggests the trend to curative treatment instead of symptom management throughout all the patient life. In addition, the fact that the current application of CRISPR is not limited by a specific blood disorder shows that a single technology tool might be modified to target many different heritable blood disorders. Assuming that the outcomes can be transferable into the human studies, it may lighten the burden of healthcare, enhance the living standards of patients, and make gene therapy a first-tier intervention in genetic haematology.

4.4. Limitations of the Study

Nevertheless, there are a number of limitations that should be admitted in spite of these encouraging findings. To begin with, no exclusive use of animal models is utilized in the study, although it is still biologically applicable, the pathophysiology of associated diseases in humans is not always identical in conditions and animal models. The immunological reaction to Cas9 proteins and delivery vectors were not thoroughly investigated, but these should be obstacles of clinical translation. As well, lifelong studies of edited animals were temporary, allowing no complete evaluation of delayed off-target effects or risks of an oncogenic transformation. Others like viral vectors had moderate off-target effect, which cast doubt on genomic safety. Second, Fanconi anemia models also exhibited low levels of therapeutic improvement, with successful editing failing to substantially benefit disease patients, suggesting that either the disease may be complex, or that the stem cells may be particularly fragile which is why therapeutic gains may turn out to be low.

4.4. Suggestions for Future Research

- Investigate the long-term effects of gene editing by performing animal studies that last long and determine the persistence of the effects as well as late arising toxicities.
- To minimize the off-target reaction and immune response, construct and screen the non-viral delivery system (e.g., lipid nanoparticles).
- Increase animal testing using larger animals (e.g. pig, primates) whose hematologic physiology resembles the experience of people more closely.
- Incorporate immune profiling to know how the hosts react to CRISPR components and enhance better immune evasion modalities.
- Explore the combination of therapies, e.g. combination of CRISPR with pharmacological agent or epigenetic modifiers in order to amplify treatment benefit in complex pediatric disorders like Fanconi anemia.
- Confirm the therapeutic effect on humanized mouse models whose hematopoiesis better duplicates that of humans.

5. CONCLUSION

The increasing potential of CRISPR-Cas9 as a revolutionary technology in the management of inherited genetically-related disorders has seen an upsurge of preclinical studies especially in the area of inherited hematologic disorders. Experimental studies on animals have also proved to be fundamental in forming the initial knowledge of how genome editing could normalize the hematologic phenotype, lower the phenotype of a disease as well as bring about persistent genome correction. This conclusion summarizes the most important results of the research, highlights the role of the research in the context of the whole

world of science and clinical practice, as well as provides the recommendations on possible ways of further development of this research area.

5.1. **Summary of Key Findings**

The study based on the in-depth review of animal trials indicates that the CRISPR-Cas9 mediated gene editing provides high effectiveness in addressing and fixing disease-causing changes linked to inherited hematologic disorders. The efficiencies of the editing that were observed in different models varied between 42 percent and 65 percent, and the respective increases in hemoglobin levels, clotting time, and in general hematologic activity, could be seen. The most significant, in particular, were the results of the β-thalassemia and hemophilia B models, in which gene correction produced a significant clinical effect. Most off-target effects values were considered moderate or weak, although most of the effects could be clinically tolerated or temporary. Also, the sickle cell models showed that in longitudinal data, therapeutic advantages as not just feasible but could be sustained going forward. All these results justify a robust preclinical proof-of-concept of CRISPR-Cas9 in correcting genetic blood diseases.

5.2**. Significance of the Study**

The importance of this study is related to the fact that animal-based evidence is its only tool, and a strong and ethically approved basis is how to examine the translation of gene editing therapies. Through the analysis of aggregated data with multiple disorders and species, the study provides the overview of the CRISPR-Cas9 performance in vivo that is impossible to see using the in vitro models only. The knowledge acquired out of this animal research is critical intermediate steps towards the human use of safe, effective and scalable gene therapies. In addition, the study emphasizes the significance of a methodic adjustment of delivery systems and better designs that will utilize to the fullest extent the editing efficiency and at the same time mitigate the negative effects. This groundbreaking study is valuable to the existing evidence of the effectiveness of gene editing in the standard of therapy in hematologic genetics.

5.3. Final Thoughts or Recommendations

As the potential of CRISPR-Cas9 has become crystal clear, care and diligence must nonetheless be the watchwords as the technology approaches clinical use. Future research measuring long-term outcomes of animal experimentation is suggested which should serve as an evaluation of the risk of genotoxicity or immunogenic reaction. Lab research must also focus more on coming up with non-viral, safer delivery systems, and more importantly increase genome-wide screening so as to decrease unwanted edits further. The combination of gene editing with adjunct therapies, e.g. epigenetic control or small molecules, might find synergies, e.g. in the case of complex diseases such as Fanconi anemia. Finally, it is essential that the CRISPR-based clinical translation is performed in a responsible and effective way because multidisciplinary effort of geneticists, hematologists, bioengineers, and ethicists indicates that they need to collaborate with each other to achieve the perceived benefits of the CRISPR technology. This research, therefore, forms a sort of a research base and call to conduct more advanced, extended, and precise studies regarding genome editing as a means of dealing with inherited blood disorders.

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation**.**

REFERENCES

1. Ugalde, L., Fañanas, S., Torres, R., Quintana-Bustamante, O., & Río, P. (2023). CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders. Cytotherapy, 25(3), 277-285.
2. Chen, Y., Wen, R., Yang, Z., & Chen, Z. (2022). Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders. Gene therapy, 29(5), 207-216.
3. Antony, J. S., Haque, A. A., Lamsfus-Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. S. (2018). CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases. Advances in Cell and Gene Therapy, 1(1), e10.
4. Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019). Therapeutic gene editing in haematological disorders with CRISPR/Cas9. British journal of haematology, 185(5), 821-835.
5. Kansal, R. (2024). The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes, 15(7), 863.
6. Levesque, S., & Bauer, D. E. (2025). CRISPR-based therapeutic genome editing for inherited blood disorders. Nature Reviews Drug Discovery, 1-19.
7. Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021). The potential of CRISPR/Cas9 gene editing as a treatment strategy for inherited diseases. Frontiers in cell and developmental biology, 9, 699597.
8. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., ... & Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252-260.
9. Anurogo, D., Yuli Prasetyo Budi, N., Thi Ngo, M. H., Huang, Y. H., & Pawitan, J. A. (2021). Cell and gene therapy for anemia: hematopoietic stem cells and gene editing. International journal of molecular sciences, 22(12), 6275.
10. Daniel-Moreno, A., Lamsfus-Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019). CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation. Bone Marrow Transplantation, 54(12), 1940-1950.
11. Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., ... & Wu, Y. (2022). CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. Nature medicine, 28(8), 1573-1580.
12. Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., ... & Miccio, A. (2018). Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood, The Journal of the American Society of Hematology, 131(17), 1960-1973.
13. Park, S. H., & Bao, G. (2021). CRISPR/Cas9 gene editing for curing sickle cell disease. Transfusion and Apheresis Science, 60(1), 103060.
14. Morishige, S., Mizuno, S., Ozawa, H., Nakamura, T., Mazahery, A., Nomura, K., ... & Nagafuji, K. (2020). CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. International journal of hematology, 111(2), 225-233.
15. Pavani, G., Fabiano, A., Laurent, M., Amor, F., Cantelli, E., Chalumeau, A., ... & Amendola, M. (2021). Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells. Blood advances, 5(5), 1137-1153.